Development of a Personalised Device for Systemic Magnetic Drug Targeting to Brain Tumours

Patel, P, Alghamdi, A, Shaw, G, Legge, C, Glover, M, Freeman, D, Hodgetts, H, Watson, E, Howard, F, Staniland, S, Kennerley, AJ ORCID: https://orcid.org/0000-0002-7599-7461, Wood, D, Moorehead, R, Hadfield, C, Rominiyi, O, Griffin, J, Collis, SJ, Hyde, S, Crossley, M, Paley, M and Muthana, M (2023) Development of a Personalised Device for Systemic Magnetic Drug Targeting to Brain Tumours. Nanotheranostics, 7 (1). pp. 102-116. ISSN 2206-7418

Preview

Published Version Available under License Creative Commons Attribution. Download (4MB) | Preview

Abstract

Delivering therapies to deeply seated brain tumours (BT) is a major clinical challenge. Magnetic drug targeting (MDT) could overcome this by rapidly transporting magnetised drugs directly into BT. We have developed a magnetic device for application in murine BT models using an array of neodymium magnets with a combined strength of 0.7T. In a closed fluidic system, the magnetic device trapped magnetic nanoparticles (MNP) up to distances of 0.8cm. In mice, the magnetic device guided intravenously administered MNP (<50nm) from the circulation into the brain where they localised within mouse BT. Furthermore, MDT of magnetised Temozolomide (TMZmag+) significantly reduced tumour growth and extended mouse survival to 48 days compared to the other treatment groups. Using the same principles, we built a proof of principle scalable magnetic device for human use with a strength of 1.1T. This magnetic device demonstrated trapping of MNP undergoing flow at distances up to 5cm. MDT using our magnetic device provides an opportunity for targeted delivery of magnetised drugs to human BT.